Who Paid My Doc
Tashanna Myers
Gynecologic Oncology Springfield, MA Medical Doctor
NPI 1821103912 CMS profile 898923
3350 Main St, 4Th Fl, Springfield, MA 01107
General payments
$4,182
Research payments
$2,679
Ownership & investment interest
$0
Research they led as principal investigator
$1,339,232
Through program year 2025, Tashanna Myers of Springfield, MA is reported in the CMS Open Payments database as having received $4,182 across 4 general payments and $2,679 in research payments paid to them. Separately, studies naming them as principal investigator received $1,339,232 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 75th percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,175 | 1 | |
| 2024 | General | $2,007 | 3 | |
| 2021 | Research | $2,137 | 6 | |
| 2020 | Research | $542 | 2 |
Beside peers
- Tashanna Myers
- Gynecologic Oncology median
- Middle half of Gynecologic Oncology
- National median
In program year 2025, general payments to Tashanna Myers were reported at $2,175. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.
Show as a table
| Year | Tashanna Myers | Gynecologic Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $287 | $113–$1,548 | $163 |
| 2020 | $0 | $223 | $59–$2,164 | $114 |
| 2021 | $0 | $193 | $68–$1,139 | $132 |
| 2022 | $0 | $252 | $90–$1,151 | $149 |
| 2023 | $0 | $281 | $102–$1,419 | $160 |
| 2024 | $2,007 | $308 | $108–$1,502 | $164 |
| 2025 | $2,175 | $305 | $111–$1,499 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
208
Drug cost
$1,815,081
Branded share of claims
53.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Lynparza Olaparib | Brand | 48 | $637,401 | |
| Lenvima Lenvatinib Mesylate | Brand | 19 | $460,444 | |
| Zejula Niraparib Tosylate | Brand | 22 | $407,352 | |
| Rubraca Rucaparib Camsylate | Brand | 11 | $190,877 | |
| Everolimus | Generic | 13 | $116,992 | |
| Letrozole | Generic | 33 | $918 | |
| Clobetasol Propionate | Generic | 11 | $575 | |
| Anastrozole | Generic | 11 | $261 | |
| Oxycodone Hcl | Generic | 28 | $204 | |
| Venlafaxine Hcl Er Venlafaxine Hcl | Brand | 12 | $57 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 860 Part D prescribers listed as Gynecological Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 52 billing codesPaid by Medicare
$82,643
Medicare patients
205
Services billed
484
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 42% | |
| Arthritis | 39% | |
| Diabetes | 25% | |
| Depression | 23% | |
| Ischemic heart disease | 18% | |
| Chronic kidney disease | 18% | |
| Osteoporosis | 15% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
12 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Gynecologic Oncology in Massachusetts
Amy Bregar
Gynecologic Oncology · Boston, MA
Whitfield Growdon
Gynecologic Oncology · Boston, MA
Alexander Melamed
Gynecologic Oncology · Boston, MA
Sarah Paraghamian
Gynecologic Oncology · Boston, MA
Michael Muto
Gynecologic Oncology · Boston, MA
Caroline Nitschmann
Gynecologic Oncology · Burlington, MA
Related records
Gynecologic Oncology in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Gynecologic Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.